Clinical trial
A Phase III Trial For Patients With Metastatic Breast Cancer
NCT00191152 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191152 |
|---|---|
| Title | A Phase III Trial For Patients With Metastatic Breast Cancer |
| Official title | Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Breast Neoplasms, Cancer of the Breast |
| Intervention type | Drug |
| Interventions | gemcitabine, docetaxel, capecitabine |
| Enrollment | 475 |
| Start date | Feb 1, 2002 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 24, 2009 |
| Countries | Argentina, Australia, Brazil, Mexico, Puerto Rico, South Korea, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: